C. Gregory Elliott
No Rating Available
(Learn About Our Rating System)

C. Gregory Elliott, MD

Languages spoken: English

  • Since July of 2007, Greg Elliott, M.D., M.A.C.P., has served as Chairman of the Department of Medicine at Intermountain Medical Center. In this position he is responsible for graduate medical education, continuing medical education, research and clinical care delivered at Intermountain Medical Center by more than 250 physicians who are board certified in internal medicine or relevant specialties of internal medicine. Prior to assuming these responsibilities, Dr. Elliott served as the Chief of the Pulmonary/Critical Care and Sleep Division at LDS Hospital.

    A 1969 graduate of Brown University, Dr. Elliott earned his M.D. with honors from the University of Maryland School of Medicine. He completed his residency and chief medical residency at the University of Maryland hospitals and he completed fellowship training in pulmonary and critical care medicine at the University of Utah hospitals in 1978. After brief service on the faculty of the University of Maryland Medical School, Dr. Elliott returned to the University of Utah School of Medicine in 1980.


    Shortly after returning to Utah, Dr. Elliott became the principal investigator of a NIH award to study primary pulmonary hypertension. He also directed research to advance the scientific basis for diagnosis, prevention, and treatment of venous thromboembolism. Known widely as an educator….. Dr. Elliott received numerous teaching awards, including the University of Utah School of Medicine Outstanding Faculty Award (1987).


    From 1997 to 2001 he served as Governor of the Utah Chapter of the American College of Physicians, and in 2003 Dr. Elliott was awarded the honor of Master of the American College of Physicians.


    Dr. Elliott has pursued research opportunities throughout his career. As an investigator he has authored or co-authored more than 100 peer-reviewed publications. He maintains an active research portfolio to advance understanding of pulmonary hypertension and venous thromboembolism. He continues to review manuscripts for leading peer reviewed scientific journals and he has served on the editorial board of CHEST since 2006. He also serves as a distinguished advisor to the scientific leadership council of the Pulmonary Hypertension Association. Greg Elliott, M.D., M.A.C.P., is the Medical Director of the Pulmonary Hypertension Center at Intermountain Medical Center. This center was established in 1983 as one of a few select centers identified by the National Institutes of Health (NIH) for the diagnosis and treatment of patients with pulmonary hypertension. The center has maintained a leading edge approach to the diagnosis and treatment of pulmonary hypertension based upon collaboration with other leading centers throughout the United States and Europe. As such, the center continues to translate basic advances to patient care. Dr. Elliott’s lifetime commitment to patients and families affected by pulmonary hypertension has earned him widespread recognition, including the Pulmonary Hypertension Association’s Outstanding Physician Award.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)

  • Since July of 2007, Greg Elliott, M.D., M.A.C.P., has served as Chairman of the Department of Medicine at Intermountain Medical Center. In this position he is responsible for graduate medical education, continuing medical education, research and clinical care delivered at Intermountain Medical Center by more than 250 physicians who are board certified in internal medicine or relevant specialties of internal medicine. Prior to assuming these responsibilities, Dr. Elliott served as the Chief of the Pulmonary/Critical Care and Sleep Division at LDS Hospital.

    A 1969 graduate of Brown University, Dr. Elliott earned his M.D. with honors from the University of Maryland School of Medicine. He completed his residency and chief medical residency at the University of Maryland hospitals and he completed fellowship training in pulmonary and critical care medicine at the University of Utah hospitals in 1978. After brief service on the faculty of the University of Maryland Medical School, Dr. Elliott returned to the University of Utah School of Medicine in 1980.


    Shortly after returning to Utah, Dr. Elliott became the principal investigator of a NIH award to study primary pulmonary hypertension. He also directed research to advance the scientific basis for diagnosis, prevention, and treatment of venous thromboembolism. Known widely as an educator….. Dr. Elliott received numerous teaching awards, including the University of Utah School of Medicine Outstanding Faculty Award (1987).


    From 1997 to 2001 he served as Governor of the Utah Chapter of the American College of Physicians, and in 2003 Dr. Elliott was awarded the honor of Master of the American College of Physicians.


    Dr. Elliott has pursued research opportunities throughout his career. As an investigator he has authored or co-authored more than 100 peer-reviewed publications. He maintains an active research portfolio to advance understanding of pulmonary hypertension and venous thromboembolism. He continues to review manuscripts for leading peer reviewed scientific journals and he has served on the editorial board of CHEST since 2006. He also serves as a distinguished advisor to the scientific leadership council of the Pulmonary Hypertension Association. Greg Elliott, M.D., M.A.C.P., is the Medical Director of the Pulmonary Hypertension Center at Intermountain Medical Center. This center was established in 1983 as one of a few select centers identified by the National Institutes of Health (NIH) for the diagnosis and treatment of patients with pulmonary hypertension. The center has maintained a leading edge approach to the diagnosis and treatment of pulmonary hypertension based upon collaboration with other leading centers throughout the United States and Europe. As such, the center continues to translate basic advances to patient care. Dr. Elliott’s lifetime commitment to patients and families affected by pulmonary hypertension has earned him widespread recognition, including the Pulmonary Hypertension Association’s Outstanding Physician Award.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Public Health
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Pulmonary Disease)

    Education history

    Chief Resident University of Maryland Chief Resident
    University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Maryland Resident
    University of Maryland Intern
    Professional Medical Medicine - University of Maryland M.D.
    Biology - Brown University B.A.

    Selected Publications

    Journal Article

    1. Scarpato BM, Locke BW, Bledsoe J, Knox DB, Conner K, Stoddard GJ, Cirulis MM, Elliott CG, Dodson MW (2023). The association between pulmonary artery enlargement and mortality in an Emergency Department population undergoing computed tomography pulmonary angiography. Pulm Circ, 13(2), e12225. (Read full article)
    2. Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC (2022). Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. J Am Heart Assoc, 11, e026229. (Read full article)
    3. Dodson MW, Cirulis MM, Elliott CG (2022). Analysis of family histories suggests shared genetic risk for chronic thromboembolic pulmonary hypertension and venous thromboembolism. Pulm Circ, 12(4), e12170. (Read full article)
    4. Spyropoulos AC, Goldin M, Ageno W, Albers GW, Elliott CG, Hiatt WR, Halperin JL, Maynard G, Steg PG, Weitz JI, Spiro TE, Lu W, Marsigliano J, Raskob GE, Barnathan ES (2022). Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open, 6(3), e177-e183. (Read full article)
    5. Cirulis MM, Knox DB, Stoddard GJ, Brown LM, Elliott CG, Brown SM, Dodson MW (2022). The CTEPH Trajectories Study: Assessment of Follow-up after Acute Pulmonary Embolism to Identify Missed Opportunities for CTEPH Diagnosis. Ann Am Thorac Soc, 19, 1428-1432. (Read full article)
    6. Dodson MW, Cirulis MM, Li H, Yue Z, Brown LM, Elliott CG (2022). Frequency of Thrombotic Risk Factors in Patients with Chronic Thromboembolic Pulmonary Hypertension and Acute Pulmonary Embolism: A Case-Control Study. Clin Appl Thromb Hemost, 28, 10760296211073277. (Read full article)
    7. Woller SC, Stevens SM, Kaplan D, Wang TF, Branch DW, Groat D, Wilson EL, Armbruster B, Aston VT, Lloyd JF, Rondina MT, Elliott CG (2021). Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv, 6(6), 1661-1670. (Read full article)
    8. Ageno W, Lopes RD, Goldin M, Yusen RD, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Weitz JI, Suh E, Lu W, Barnathan ES, Raskob GE, Spyropoulos AC (2021). Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older. J Thromb Haemost, 19, 2772-2780. (Read full article)
    9. Bledsoe JR, Kelly C, Stevens SM, Woller SC, Haug P, Lloyd JF, Allen TL, Butler AM, Jacobs JR, Elliott CG (2021). Electronic pulmonary embolism clinical decision support and effect on yield of computerized tomographic pulmonary angiography: ePE-A pragmatic prospective cohort study. J Am Coll Emerg Physicians Open, 2(4), e12488. (Read full article)
    10. Elliott CG (2021). Genetic Counseling and Testing in Pulmonary Arterial Hypertension. Methodist Debakey Cardiovasc J, 17(2), 101-105. (Read full article)
    11. Maron BA, Abman SH, Elliott CG, Frantz RP, Hopper RK, Horn EM, Nicolls MR, Shlobin OA, Shah SJ, Kovacs G, Olschewski H, Rosenzweig EB (2021). Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. Am J Respir Crit Care Med, 203(12), 1472-1487. (Read full article)
    12. Badlam JB, Badesch DB, Austin ED, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC, Elliott CG (2021). United States Pulmonary Hypertension Scientific Registry Baseline Characteristics. Chest, 159(1), 311-327.
    13. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, Elliott CG, Farber HW (2021). Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest, 159(1), 337-346.
    14. Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE (2020). Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J Am Coll Cardiol, 75(25), 3140-3147. (Read full article)
    15. Elliott CG, Austin ED, Badesch D, Badlam J, Benza RL, Chung WK, Farber HW, Feldkircher K, Frost AE, Poms AD, Lutz KA, Pauciulo MW, Yu C, Nichols WC (2019). United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulm Circ, 9(2), 2045894019851696. (Read full article)
    16. Willoughby L, Adams DM, Evans RS, Lloyd JF, Stevens SM, Woller SC, Bledsoe JR, Aston VT, Wilson EL, Elliott CG (2017). Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism: Are Guidelines Followed? Chest, 153(5), 1153-1159. (Read full article)
    17. Chaisson NF, Dodson MW, Elliott CG (2016). Pulmonary Capillary Hemangiomatosis and Pulmonary Veno-occlusive Disease. Clin Chest Med, 37(3), 523-34. (Read full article)
    18. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI (2016). The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost, 115(6), 1240-8. (Read full article)
    19. Desmarais J, Elliott CG (2015). Familial Chronic Thromboembolic Pulmonary Hypertension. Chest, 149(4), e99-e101. (Read full article)
    20. Evans JD, Girerd B, Montani D, Wang XJ, Gali N, Austin ED, Elliott G, Asano K, Grnig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Grf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW (2016). BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med, 4(2), 129-37. (Read full article)
    21. Kaplan D, Casper TC, Elliott CG, Men S, Pendleton RC, Kraiss LW, Weyrich AS, Grissom CK, Zimmerman GA, Rondina MT (2015). VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. Chest, 148(5), 1224-1230. (Read full article)
    22. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG, McGoon MD, Benza RL (2015). Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest, 148(4), 1043-54. (Read full article)
    23. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, Lemari JC, Miller DP, Muros-Le Rouzic E, Simonneau G, Frost AE, Farber HW, Humbert M, McGoon MD (2015). Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J, 46(1), 152-64. (Read full article)
    24. Woller SC, Stevens SM, Towner S, Olson J, Christensen P, Hamilton S, Newman L, Mott L, Hu P, Brunisholz KD, Long Y, Lloyd J, Evans RS, Cannon W, Elliott CG (2014). Computerized clinical decision support improves warfarin management and decreases recurrent venous thromboembolism. Clin Appl Thromb Hemost, 21(3), 197-203. (Read full article)
    25. Woller SC, Stevens SM, Adams DM, Evans RS, Lloyd JF, Snow GL, Bledsoe JR, Gay DZ, Patten RM, Aston VT, Elliott CG (2014). Assessment of the safety and efficiency of using an age-adjusted D-dimer threshold to exclude suspected pulmonary embolism. Chest, 146(6), 1444-1451. (Read full article)
    26. Best DH, Austin ED, Chung WK, Elliott CG (2014). Genetics of pulmonary hypertension. Curr Opin Cardiol, 29(6), 520-7. (Read full article)
    27. Taichman DB, Ornelas J, Chung L, Klinger JR, Lewis S, Mandel J, Palevsky HI, Rich S, Sood N, Rosenzweig EB, Trow TK, Yung R, Elliott CG, Badesch DB (2014). Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest, 146(2), 449-475. (Read full article)
    28. Elliott CG (2014). Robyn j. Barst, MD. Pulm Circ, 3(4), 968. (Read full article)
    29. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD (2012). Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest, 143(1), 185-195. (Read full article)
    30. Adams DM, Stevens SM, Woller SC, Evans RS, Lloyd JF, Snow GL, Allen TL, Bledsoe JR, Brown LM, Blagev DP, Lovelace TD, Shill TL, Conner KE, Aston VT, Elliott CG (2012). Adherence to PIOPED II investigators' recommendations for computed tomography pulmonary angiography. Am J Med, 126(1), 36-42. (Read full article)
    31. Brown SM, Elliott CG, Paine R (2013). Withdrawal of nonfutile life support after attempted suicide. Am J Bioeth, 13(3), 3-12. (Read full article)
    32. Brown SM, Elliott CG, Paine R (2013). Response to open peer commentaries on "Withdrawal of nonfutile life support after attempted suicide". Am J Bioeth, 13(3), W3-5. (Read full article)
    33. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, Miller DP, Elliott CG (2011). Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest, 140(1), 19-26. (Read full article)
    34. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD (2010). The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest, 139(1), 128-37. (Read full article)
    35. Trow TK, Elliott CG (2010). Venous thromboembolism. Preface. Clin Chest Med, 31(4), xi-xii. (Read full article)
    36. Elliott CG, Barst RJ, Seeger W, Porres-Aguilar M, Brown LM, Zamanian RT, Rubin LJ (2010). Worldwide physician education and training in pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest, 137(6 Suppl), 85S-94S. (Read full article)
    37. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD (2009). Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest, 137(2), 376-87. (Read full article)
    38. Sundar KM, Elliott CG, Thomsen GE (2001). Tetracycline aspiration. Case report and review of the literature. Respiration, 68(4), 416-9. (Read full article)
    39. Tapson VF, Carroll BA, Davidson BL, Elliott CG, Fedullo PF, Hales CA, Hull RD, Hyers TM, Leeper KV Jr, Morris TA, Moser KM, Raskob GE, Shure D, Sostman HD, Taylor Thompson B (1999). The diagnostic approach to acute venous thromboembolism. Clinical practice guideline. American Thoracic Society. Am J Respir Crit Care Med, 160(3), 1043-66. (Read full article)

    Review

    1. Elliott G (1999). Thrombolytic therapy for venous thromboembolism. [Review]. Curr Opin Hematol, 6(5), 304-8. (Read full article)

    Case Report

    1. Oriaku I, LeSieur MN, Nichols WC, Barrios R, Elliott CG, Frost A (2020). A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype. Pulm Circ, 10(3), 2045894020931315. (Read full article)

    Editorial

    1. Davidson BL, Tapson VF, Irwin RS, French CL, Elliott CG, Levi M (2020). Pharyngeal Antisepsis to Reduce COVID-19 Pneumonia. Am J Med, 134(3), 297-298. (Read full article)
    2. Elliott CG, Hill NS (2020). One for the Ages. Chest, 158(3), 856-857. (Read full article)
    3. Austin ED, Elliott CG (2020). TBX4 syndrome: a systemic disease highlighted by pulmonary arterial hypertension in its most severe form. Eur Respir J, 55(5). (Read full article)
    4. Elliott CG, Brown LM (2009). Pulmonary embolism: another piece of the puzzle? Chest, 136(5), 1193-1194. (Read full article)

    Letter

    1. Dodson MW, Sumner K, Carlsen J, Cirulis MM, Wilson EL, Gadre A, Fernandes TM, Brown LM, Best DH, Elliott CG (2020). The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension. [Letter to the editor]. Eur Respir J, 56(4). (Read full article)
    2. Elliott CG, Orme J Jr, Weaver LK (2019). Pneumatic Compression in Venous Thromboprophylaxis. [Letter to the editor]. N Engl J Med, 381(1), 94. (Read full article)
    3. Klinger JR, Elliott G, Levine DJ, Bossone E, Duvall L, Fagan K, Frantsve-Hawley J, Kawut SM, Ryan JJ, Rosenzweig EB, Sederstrom N, Steen VD, Badesch DB (2019). Response. [Letter to the editor]. Chest, 156(1), 187-188. (Read full article)
    4. Ghio AJ, Crapo RO, Elliott CG (1990). Survey of reference equations used to predict pulmonary function in children. [Letter to the editor]. Pediatr Pulmonol, 8(2), 126-7. (Read full article)

    Other

    1. Kerr KM, Elliott CG, Chin K, Benza RL, Channick RN, Davis RD, He F, LaCroix A, Madani MM, McLaughlin VV, Park M, Robbins IM, Tapson VF, Terry JR, Test VJ, Jain S, Auger WR (2021). Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up. Chest (160(5), pp. 1822-1831). United States. (Read full article)